Invasive Pulmonary Aspergillosis

 

 Buy Article Permissions and Reprints

Invasive pulmonary aspergillosis (IPA) is the most common fungal pulmonary infection in severely immunocompromised patients. Aspergillus species are commonly isolated from the soil, plant debris, and the indoor environment, including the hospital. Phagocytosis is the main host defense against Aspergillus conidia and hyphae. The diagnosis of IPA is based on clinical, radiological, and mycological data. Clinical signs have a low specificity. The most typical computed tomographic (CT) findings are nodules with or without the halo sign or the air crescent sign. Sensitivity of microscopy and culture of noninvasive collected samples is low. Galactomannan and nucleic acid detection in serum or in bronchoalveolar lavage (BAL) fluid help to confirm the diagnosis. Crude mortality is high and strongly correlated with the underlying condition, stage of the underlying disease, and extension of the aspergillosis. Optimal therapeutic strategies include the prevention of contamination in patients at high risk, early initiation of antifungal therapy, surgery in some instances, and, importantly, treatment of the underlying condition to restore whenever possible a certain degree of immunocompetence. Voriconazole has demonstrated better efficacy and safety than amphotericin B deoxycholate. The improved survival observed with voriconazole makes it a new reference for the first-line therapy of IA. Lipid formulations of amphotericin B, caspofungin, micafungin, and posaconazole are other therapeutic options in the event of failure of or contraindication to voriconazole. The main indication for surgery is prevention of severe hemoptysis when the lesion is adjacent to a large vessel.

REFERENCES

• 1 Cornet M, Fleury L, Maslo C et al.. Epidemiology of IA in France: a six-year multicentric survey in the Greater Paris area.  J Hosp Infect. 2002;  51 288-296
  CrossrefPubMedGoogle Scholar
• 2 Dasbach E J, Davies G M, Teutsch S M. Burden of aspergillosis-related hospitalizations in the United States.  Clin Infect Dis. 2000;  31 1524-1528
  CrossrefPubMedGoogle Scholar
• 3 Chandrasekar P H, Weinmann A, Shearer C. Autopsy-identified infections among bone marrow transplant recipients: a clinico-pathologic study of 56 patients. Bone Marrow Transplantation Team.  Bone Marrow Transplant. 1995;  16 675-681
  PubMedGoogle Scholar
• 4 Ascioglu S, Rex J H, de Pauw B et al.. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.  Clin Infect Dis. 2002;  34 7-14
  CrossrefPubMedGoogle Scholar
• 5 Faure O, Fricker-Hidalgo H, Lebeau B et al.. Eight-year surveillance of environmental fungal contamination in hospital operating rooms and haematological units.  J Hosp Infect. 2002;  50 155-160
  CrossrefPubMedGoogle Scholar
• 6 Lass-Florl C, Rath P, Niederwieser D et al.. Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants.  J Hosp Infect. 2000;  46 31-35
  CrossrefPubMedGoogle Scholar
• 7 Burwen D R, Lasker B A, Rao N et al.. IA outbreak on a hematology-oncology ward.  Infect Control Hosp Epidemiol. 2001;  22 45-48
  CrossrefPubMedGoogle Scholar
• 8 Loo V G, Bertrand C, Dixon C et al.. Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit.  Infect Control Hosp Epidemiol. 1996;  17 360-364
  PubMedGoogle Scholar
• 9 Denning D W. IA.  Clin Infect Dis. 1998;  26 781-803
  CrossrefPubMedGoogle Scholar
• 10 Anaissie E J, Penzak S R, Dignani M C. The hospital water supply as a source of nosocomial infections: a plea for action.  Arch Intern Med. 2002;  162 1483-1492
  CrossrefPubMedGoogle Scholar
• 11 Iwen P C, Rupp M E, Langnas A N et al.. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature.  Clin Infect Dis. 1998;  26 1092-1097
  CrossrefPubMedGoogle Scholar
• 12 Grossi P, Farina C, Fiocchi R et al.. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients.  Transplantation. 2000;  70 112-116
  PubMedGoogle Scholar
• 13 Latge J P. Aspergillus fumigatus and aspergillosis.  Clin Microbiol Rev. 1999;  12 310-350
  PubMedGoogle Scholar
• 14 Philippe B, Ibrahim-Granet O, Prevost M C et al.. Killing of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates.  Infect Immun. 2003;  71 3034-3042
  CrossrefPubMedGoogle Scholar
• 15 Hebart H, Bollinger C, Fisch P et al.. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies.  Blood. 2002;  100 4521-4528
  CrossrefPubMedGoogle Scholar
• 16 Gerson S L, Talbot G H, Hurwitz S et al.. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia.  Ann Intern Med. 1984;  100 345-351
  PubMedGoogle Scholar
• 17 Agusti C, Rano A, Filella X et al.. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response.  Chest. 2003;  123 488-498
  CrossrefPubMedGoogle Scholar
• 18 Wald A, Leisenring W, van Burik J A et al.. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation.  J Infect Dis. 1997;  175 1459-1466
  CrossrefPubMedGoogle Scholar
• 19 Dimopoulos G, Piagnerelli M, Berre J et al.. Disseminated aspergillosis in intensive care unit patients: an autopsy study.  J Chemother. 2003;  15 71-75
  PubMedGoogle Scholar
• 20 Rello J, Esandi M E, Mariscal D et al.. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review.  Clin Infect Dis. 1998;  26 1473-1475
  CrossrefPubMedGoogle Scholar
• 21 Singh N, Arnow P M, Bonham A et al.. IA in liver transplant recipients in the 1990s.  Transplantation. 1997;  64 716-720
  CrossrefPubMedGoogle Scholar
• 22 Allam M F, Del Castillo A S, Diaz-Molina C et al.. Invasive pulmonary aspergillosis: identification of risk factors.  Scand J Infect Dis. 2002;  34 819-822
  PubMedGoogle Scholar
• 23 Lin S J, Schranz J, Teutsch S M. Aspergillosis case-fatality rate: systematic review of the literature.  Clin Infect Dis. 2001;  32 358-366
  CrossrefPubMedGoogle Scholar
• 24 Martino R, Lopez R, Sureda A et al.. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy: a single-center experience and review of the literature.  Haematologica. 1997;  82 297-304
  PubMedGoogle Scholar
• 25 Offner F, Cordonnier C, Ljungman P et al.. Impact of previous aspergillosis on the outcome of bone marrow transplantation.  Clin Infect Dis. 1998;  26 1098-1103
  PubMedGoogle Scholar
• 26 Marr K A, Carter R A, Boeckh M et al.. IA in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.  Blood. 2002;  100 4358-4366
  CrossrefPubMedGoogle Scholar
• 27 Patterson J E, Peters J, Calhoon J H et al.. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients.  Transpl Infect Dis. 2000;  2 22-28
  CrossrefPubMedGoogle Scholar
• 28 Mehrad B, Paciocco G, Martinez F J et al.. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature.  Chest. 2001;  119 169-175
  CrossrefPubMedGoogle Scholar
• 29 Minari A, Husni R, Avery R K et al.. The incidence of IA among solid organ transplant recipients and implications for prophylaxis in lung transplants.  Transpl Infect Dis. 2002;  4 195-200
  CrossrefPubMedGoogle Scholar
• 30 Gordon S M, Avery R K. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies.  Transpl Infect Dis. 2001;  3 161-167
  CrossrefPubMedGoogle Scholar
• 31 Cahill B C, Hibbs J R, Savik K et al.. Aspergillus airway colonization and invasive disease after lung transplantation.  Chest. 1997;  112 1160-1164
  CrossrefPubMedGoogle Scholar
• 32 Fortun J, Martin-Davila P, Moreno S et al.. Risk factors for IA in liver transplant recipients.  Liver Transpl. 2002;  8 1065-1070
  CrossrefPubMedGoogle Scholar
• 33 Singh N, Avery R K, Munoz P et al.. Trends in risk profiles for and mortality associated with IA among liver transplant recipients.  Clin Infect Dis. 2003;  36 46-52
  CrossrefPubMedGoogle Scholar
• 34 Panackal A A, Dahlman A, Keil K T et al.. Outbreak of IA among renal transplant recipients.  Transplantation. 2003;  75 1050-1053
  PubMedGoogle Scholar
• 35 Groll A H, Kurz M, Schneider W et al.. Five-year-survey of IA in a paediatric cancer centre: epidemiology, management and long-term survival.  Mycoses. 1999;  42 431-442
  CrossrefPubMedGoogle Scholar
• 36 Denning D W, Marinus A, Cohen J et al.. An EORTC multicentre prospective survey of IA in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group.  J Infect. 1998;  37 173-180
  CrossrefPubMedGoogle Scholar
• 37 Lortholary O, Ascioglu S, Moreau P et al.. IA as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myelome.  Clin Infect Dis. 2000;  30 41-46
  CrossrefPubMedGoogle Scholar
• 38 Shetty D, Giri N, Gonzalez C E et al.. IA in human immunodeficiency virus-infected children.  Pediatr Infect Dis J. 1997;  16 216-221
  CrossrefPubMedGoogle Scholar
• 39 Wallace J M, Lim R, Browdy B L et al.. Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group.  Chest. 1998;  114 131-137
  CrossrefPubMedGoogle Scholar
• 40 Mylonakis E, Barlam T F, Flanigan T et al.. Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases.  Chest. 1998;  114 251-262
  CrossrefPubMedGoogle Scholar
• 41 Mouy R, Veber F, Blanche S et al.. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease.  J Pediatr. 1994;  125 998-1003
  PubMedGoogle Scholar
• 42 Chudwin D S, Wara D W, Cowan M J et al.. Aspergillus pneumonia in chronic granulomatous disease: recurrence and long-term outcome.  Acta Paediatr Scand. 1982;  71 915-917
  PubMedGoogle Scholar
• 43 Lundin J, Hagberg H, Repp R et al.. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.  Blood. 2003;  101 4267-4272
  CrossrefPubMedGoogle Scholar
• 44 Kim W U, Kim S I, Yoo W H et al.. Adult respiratory distress syndrome in systemic lupus erythematosus: causes and prognostic factors: a single center, retrospective study.  Lupus. 1999;  8 552-557
  CrossrefPubMedGoogle Scholar
• 45 Garrett D O, Jochimsen E, Jarvis W. Invasive Aspergillus spp. infections in rheumatology patients.  J Rheumatol. 1999;  26 146-149
  PubMedGoogle Scholar
• 46 Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy.  N Engl J Med. 2001;  344 1099-1100
  CrossrefPubMedGoogle Scholar
• 47 De Rosa F G, Shaz D, Campagna A C et al.. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?.  Infect Control Hosp Epidemiol. 2003;  24 477-482
  CrossrefPubMedGoogle Scholar
• 48 Karim M, Alam M, Shah A A et al.. Chronic IA in apparently immunocompetent hosts.  Clin Infect Dis. 1997;  24 723-733
  CrossrefPubMedGoogle Scholar
• 49 Patterson T F, Kirkpatrick W R, White M et al.. IA: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.  Medicine (Baltimore). 2000;  79 250-260
  CrossrefPubMedGoogle Scholar
• 50 Brenier-Pinchart M P, Lebeau B, Devouassoux G et al.. Aspergillus and lung transplant recipients: a mycologic and molecular epidemiologic study.  J Heart Lung Transplant. 1998;  17 972-979
  PubMedGoogle Scholar
• 51 Helmi M, Love R B, Welter D et al.. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients.  Chest. 2003;  123 800-808
  CrossrefPubMedGoogle Scholar
• 52 Subira M, Martino R, Rovira M et al.. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed IA.  Ann Hematol. 2003;  82 80-82
  PubMedGoogle Scholar
• 53 Hauggaard A, Ellis M, Ekelund L. Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis.  Acta Radiol. 2002;  43 292-298
  CrossrefPubMedGoogle Scholar
• 54 Greene R E, Schlamm H T, Stark P et al.. Radiological findings in acute invasive pulmonary aspergillosis: utility and reliability of halo sign and air-crescent sign for diagnosis and treatment of IPA in high-risk patients. Proceedings of the 13th European Congress of Clinical Microbiology and Infectious Diseases May 10-13, 2003 Glasgow, Scotland;
  Google Scholar
• 55 Herbrecht R, Denning D W, Patterson T F et al.. Voriconazole versus amphotericin B for primary therapy of IA.  N Engl J Med. 2002;  347 408-415
  CrossrefPubMedGoogle Scholar
• 56 von Eiff M, Roos N, Schulten R et al.. Pulmonary aspergillosis: early diagnosis improves survival.  Respiration. 1995;  62 341-347
  CrossrefPubMedGoogle Scholar
• 57 Westney G E, Kesten S, De Hoyos A et al.. Aspergillus infection in single and double lung transplant recipients.  Transplantation. 1996;  61 915-919
  CrossrefPubMedGoogle Scholar
• 58 Caillot D, Casasnovas O, Bernard A et al.. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery.  J Clin Oncol. 1997;  15 139-147
  CrossrefPubMedGoogle Scholar
• 59 Brown M J, Worthy S A, Flint J D et al.. IA in the immunocompromised host: utility of computed tomography and bronchoalveolar lavage.  Clin Radiol. 1998;  53 255-257
  PubMedGoogle Scholar
• 60 Burt M E, Flye M W, Webber B L et al.. Prospective evaluation of aspiration needle, cutting needle, transbronchial, and open lung biopsy in patients with pulmonary infiltrates.  Ann Thorac Surg. 1981;  32 146-153
  PubMedGoogle Scholar
• 61 Pagano L, Girmenia C, Mele L et al.. Infections caused by filamentous fungi in patients with hematologic malignancies: a report of 391 cases by GIMEMA Infection Program.  Haematologica. 2001;  86 862-870
  PubMedGoogle Scholar
• 62 Andreas S, Heindl S, Wattky C et al.. Diagnosis of pulmonary aspergillosis using optical brighteners.  Eur Respir J. 2000;  15 407-411
  CrossrefPubMedGoogle Scholar
• 63 Kontoyiannis D P, Sumoza D, Tarrand J et al.. Significance of aspergillemia in patients with cancer: a 10-year study.  Clin Infect Dis. 2000;  31 188-189
  CrossrefPubMedGoogle Scholar
• 64 Girmenia C, Nucci M, Martino P. Clinical significance of Aspergillus fungaemia in patients with haematological malignancies and IA.  Br J Haematol. 2001;  114 93-98
  CrossrefPubMedGoogle Scholar
• 65 Maertens J, Verhaegen J, Demuynck H et al.. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for IA.  J Clin Microbiol. 1999;  37 3223-3228
  CrossrefPubMedGoogle Scholar
• 66 Maertens J, Verhaegen J, Lagrou K et al.. Screening for circulating galactomannan as a noninvasive diagnostic tool for IA in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.  Blood. 2001;  97 1604-1610
  CrossrefPubMedGoogle Scholar
• 67 Sulahian A, Tabouret M, Ribaud P et al.. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of IA.  Eur J Clin Microbiol Infect Dis. 1996;  15 139-145
  CrossrefPubMedGoogle Scholar
• 68 Verweij P E, Stynen D, Rijs A J et al.. Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing IA in immunocompromised patients.  J Clin Microbiol. 1995;  33 1912-1914
  PubMedGoogle Scholar
• 69 Herbrecht R, Letscher-Bru V, Oprea C et al.. Aspergillus galactomannan detection in the diagnosis of IA in cancer patients.  J Clin Oncol. 2002;  20 1898-1906
  CrossrefPubMedGoogle Scholar
• 70 Siemann M, Koch-Dorfler M, Gaude M. False-positive results in premature infants with the Platelia Aspergillus sandwich enzyme-linked immunosorbent assay.  Mycoses. 1998;  41 373-377
  PubMedGoogle Scholar
• 71 Gangneux J P, Lavarde D, Bretagne S et al.. Transient Aspergillus antigenaemia: think of milk.  Lancet. 2002;  359 1251
  PubMedGoogle Scholar
• 72 Ansorg R, van den Boom R, Rath P M. Detection of Aspergillus galactomannan antigen in foods and antibiotics.  Mycoses. 1997;  40 353-357
  PubMedGoogle Scholar
• 73 Becker M J, Lugtenburg E J, Cornelissen J J et al.. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis.  Br J Haematol. 2003;  121 448-457
  CrossrefPubMedGoogle Scholar
• 74 Bretagne S, Costa J M, Marmorat-Khuong A et al.. Detection of Aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR.  J Clin Microbiol. 1995;  33 1164-1168
  PubMedGoogle Scholar
• 75 Raad I, Hanna H, Huaringa A et al.. Diagnosis of invasive pulmonary aspergillosis using polymerase chain reaction-based detection of Aspergillus in BAL.  Chest. 2002;  121 1171-1176
  CrossrefPubMedGoogle Scholar
• 76 Spiess B, Buchheidt D, Baust C et al.. Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients.  J Clin Microbiol. 2003;  41 1811-1818
  CrossrefPubMedGoogle Scholar
• 77 Kami M, Fukui T, Ogawa S et al.. Use of real-time PCR on blood samples for diagnosis of IA.  Clin Infect Dis. 2001;  33 1504-1512
  CrossrefPubMedGoogle Scholar
• 78 Einsele H, Hebart H, Roller G et al.. Detection and identification of fungal pathogens in blood by using molecular probes.  J Clin Microbiol. 1997;  35 1353-1360
  PubMedGoogle Scholar
• 79 Hebart H, Loffler J, Meisner C et al.. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening.  J Infect Dis. 2000;  181 1713-1719
  CrossrefPubMedGoogle Scholar
• 80 Hebart H, Loffler J, Reitze H et al.. Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia.  Br J Haematol. 2000;  111 635-640
  CrossrefPubMedGoogle Scholar
• 81 Einsele H, Quabeck K, Muller K D et al.. Prediction of invasive pulmonary aspergillosis from colonisation of lower respiratory tract before marrow transplantation.  Lancet. 1998;  352 1443
  PubMedGoogle Scholar
• 82 Nash G, Irvine R, Kerschmann R L et al.. Pulmonary aspergillosis in acquired immune deficiency syndrome: autopsy study of an emerging pulmonary complication of human immunodeficiency virus infection.  Hum Pathol. 1997;  28 1268-1275
  CrossrefPubMedGoogle Scholar
• 83 Franquet T, Serrano F, Gimenez A et al.. Necrotizing aspergillosis of large airways: CT findings in eight patients.  J Comput Assist Tomogr. 2002;  26 342-345
  CrossrefPubMedGoogle Scholar
• 84 Denning D W. Therapeutic outcome in IA.  Clin Infect Dis. 1996;  23 608-615
  CrossrefPubMedGoogle Scholar
• 85 Boutboul F, Alberti C, Leblanc T et al.. IA in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease.  Clin Infect Dis. 2002;  34 939-943
  CrossrefPubMedGoogle Scholar
• 86 Groll A H, Shah P M, Mentzel C et al.. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.  J Infect. 1996;  33 23-32
  CrossrefPubMedGoogle Scholar
• 87 Ribaud P, Chastang C, Latge J P et al.. Survival and prognostic factors of IA after allogeneic bone marrow transplantation.  Clin Infect Dis. 1999;  28 322-330
  PubMedGoogle Scholar
• 88 Yeghen T, Kibbler C C, Prentice H G et al.. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution.  Clin Infect Dis. 2000;  31 859-868
  CrossrefPubMedGoogle Scholar
• 89 Subira M, Martino R, Franquet T et al.. Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors.  Haematologica. 2002;  87 528-534
  PubMedGoogle Scholar
• 90 Caillot D, Couaillier J F, Bernard A et al.. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia.  J Clin Oncol. 2001;  19 253-259
  CrossrefPubMedGoogle Scholar
• 91 Withington S, Chambers S T, Beard M E et al.. IA in severely neutropenic patients over 18 years: impact of intranasal amphotericin B and HEPA filtration.  J Hosp Infect. 1998;  38 11-18
  CrossrefPubMedGoogle Scholar
• 92 Oren I, Haddad N, Finkelstein R et al.. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters.  Am J Hematol. 2001;  66 257-262
  CrossrefPubMedGoogle Scholar
• 93 Cornet M, Levy V, Fleury L et al.. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation.  Infect Control Hosp Epidemiol. 1999;  20 508-513
  PubMedGoogle Scholar
• 94 Morgenstern G R, Prentice A G, Prentice H G et al.. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.  Br J Haematol. 1999;  105 901-911
  CrossrefPubMedGoogle Scholar
• 95 Kibbler C C. Antifungal prophylaxis with itraconazole oral solution in neutropenic patients.  Mycoses. 1999;  42(suppl 2) S121-S124
  PubMedGoogle Scholar
• 96 Nucci M, Biasoli I, Akiti T et al.. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients.  Clin Infect Dis. 2000;  30 300-305
  CrossrefPubMedGoogle Scholar
• 97 Herbrecht R, Neuville S, Letscher-Bru V et al.. Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment.  Drugs Aging. 2000;  17 339-351
  PubMedGoogle Scholar
• 98 Harousseau J L, Dekker A W, Stamatoullas-Bastard A et al.. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.  Antimicrob Agents Chemother. 2000;  44 1887-1893
  CrossrefPubMedGoogle Scholar
• 99 Glasmacher A, Hahn A, Molitor E et al.. Itraconazole for antifungal prophylaxis in neutropenic patients: a meta-analysis of 2181 patients. American Society for Microbiology, Washington DC. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract J-681 p. 378 2001 Chicago, IL;
  Google Scholar
• 100 Tollemar J, Ringden O, Andersson S et al.. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.  Bone Marrow Transplant. 1993;  12 577-582
  PubMedGoogle Scholar
• 101 Schwartz S, Behre G, Heinemann V et al.. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial.  Blood. 1999;  93 3654-3661
  PubMedGoogle Scholar
• 102 Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.  Transpl Infect Dis. 1999;  1 273-283
  CrossrefPubMedGoogle Scholar
• 103 Bowden R, Chandrasekar P, White M H et al.. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of IA in immunocompromised patients.  Clin Infect Dis. 2002;  35 359-366
  CrossrefPubMedGoogle Scholar
• 104 Wingard J R, Kubilis P, Lee L et al.. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.  Clin Infect Dis. 1999;  29 1402-1407
  CrossrefPubMedGoogle Scholar
• 105 Leenders A C, Daenen S, Jansen R L et al.. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections.  Br J Haematol. 1998;  103 205-212
  CrossrefPubMedGoogle Scholar
• 106 Linden P K, Coley K, Fontes P et al.. IA in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B.  Clin Infect Dis. 2003;  37 17-25
  CrossrefPubMedGoogle Scholar
• 107 Barrett J P, Vardulaki K A, Conlon C et al.. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.  Clin Ther. 2003;  25 1295-1320
  CrossrefPubMedGoogle Scholar
• 108 Wingard J R, White M H, Anaissie E et al.. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.  Clin Infect Dis. 2000;  31 1155-1163
  CrossrefPubMedGoogle Scholar
• 109 Johnson L B, Kauffman C A. Voriconazole: a new triazole antifungal agent.  Clin Infect Dis. 2003;  36 630-637
  CrossrefPubMedGoogle Scholar
• 110 Denning D W, Ribaud P, Milpied N et al.. Efficacy and safety of voriconazole in the treatment of acute IA.  Clin Infect Dis. 2002;  34 563-571
  CrossrefPubMedGoogle Scholar
• 111 Caillot D, Bassaris H, McGeer A et al.. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.  Clin Infect Dis. 2001;  33 e83-e90
  CrossrefPubMedGoogle Scholar
• 112 Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis.  Acta Haematol. 2003;  109 111-118
  CrossrefPubMedGoogle Scholar
• 113 Denning D W, Lee J Y, Hostetler J S et al.. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for IA.  Am J Med. 1994;  97 135-144
  CrossrefPubMedGoogle Scholar
• 114 Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients.  J Am Acad Dermatol. 1990;  23 607-614
  CrossrefPubMedGoogle Scholar
• 115 Maertens J, Raad I, Sable C A et al.. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with IA refractory or intolerant to amphotericin B, AMB lipid formulations, or azoles. American Society for Microbiology, Washington DC. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract J-1103 371 2000 Toronto, Canada;
  Google Scholar
• 116 Salerno C T, Ouyang D W, Pederson T S et al.. Surgical therapy for pulmonary aspergillosis in immunocompromised patients.  Ann Thorac Surg. 1998;  65 1415-1419
  CrossrefPubMedGoogle Scholar

Raoul HerbrechtM.D. 

Département d'Hématologie et d'Oncologie, Hôpital de Hautepierre

67098 Strasbourg, France

Email: raoul.herbrecht@chru-strasbourg.fr